No­vo nabs over a third of di­a­betes mar­ket, a year ahead of sched­ule

No­vo Nordisk’s GLP-1 drugs may have been the cen­ter of at­ten­tion dur­ing its first-quar­ter earn­ings call, but the com­pa­ny’s broad­er di­a­betes port­fo­lio beat its tar­get for a greater glob­al mar­ket stake one year ear­ly.

Over the past 12 months, No­vo’s share in the di­a­betes mar­ket has grown from 32.2% to 34%, which “is above our [orig­i­nal] strate­gic as­pi­ra­tion,” head of com­mer­cial strat­e­gy and cor­po­rate af­fairs Camil­la Sylvest said on Thurs­day’s in­vestor call. Dur­ing its Cap­i­tal Mar­kets Day in 2019, No­vo set the goal of se­cur­ing one-third of the glob­al di­a­betes mar­ket by 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER